tetano
Editor, Senior Moderator
Respir Med Case Rep
. 2022;36:101618.
doi: 10.1016/j.rmcr.2022.101618. Epub 2022 Feb 20.
Interstitial lung disease after receiving the mRNA-based COVID-19 vaccine tozinameran
Naohiro Oda[SUP] 1 [/SUP], Reo Mitani[SUP] 1 [/SUP], Ichiro Takata[SUP] 1 [/SUP], Mikio Kataoka[SUP] 2 [/SUP]
Affiliations
Abstract
Tozinameran, a messenger ribonucleic acid (mRNA)-based coronavirus disease 19 (COVID-19) vaccine, has a favorable safety profile and is highly efficacious in preventing COVID-19. Adverse reactions such as pain at the vaccination site, fever, malaise, headache, rash, and anaphylaxis have been commonly reported for mRNA-based COVID-19 vaccines. We report a case involving a 71-year-old Japanese woman who developed interstitial lung disease (ILD) after receiving an mRNA-based COVID-19 vaccine. We also review case reports of COVID-19 mRNA vaccine-associated ILD. Dyspnea or hypoxia that develops within 1-3 days after COVID-19 mRNA vaccination should be differentiated from ILD. Further studies to elucidate mechanisms and risk factors of rare adverse reactions such as ILD are warranted.
. 2022;36:101618.
doi: 10.1016/j.rmcr.2022.101618. Epub 2022 Feb 20.
Interstitial lung disease after receiving the mRNA-based COVID-19 vaccine tozinameran
Naohiro Oda[SUP] 1 [/SUP], Reo Mitani[SUP] 1 [/SUP], Ichiro Takata[SUP] 1 [/SUP], Mikio Kataoka[SUP] 2 [/SUP]
Affiliations
- PMID: 35223425
- PMCID: PMC8858430
- DOI: 10.1016/j.rmcr.2022.101618
Abstract
Tozinameran, a messenger ribonucleic acid (mRNA)-based coronavirus disease 19 (COVID-19) vaccine, has a favorable safety profile and is highly efficacious in preventing COVID-19. Adverse reactions such as pain at the vaccination site, fever, malaise, headache, rash, and anaphylaxis have been commonly reported for mRNA-based COVID-19 vaccines. We report a case involving a 71-year-old Japanese woman who developed interstitial lung disease (ILD) after receiving an mRNA-based COVID-19 vaccine. We also review case reports of COVID-19 mRNA vaccine-associated ILD. Dyspnea or hypoxia that develops within 1-3 days after COVID-19 mRNA vaccination should be differentiated from ILD. Further studies to elucidate mechanisms and risk factors of rare adverse reactions such as ILD are warranted.